Literature DB >> 11430892

The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat.

J D Classey1, Y E Knight, P J Goadsby.   

Abstract

Expression of Fos protein is an indicator of neuronal perturbation and is readily observed in the caudal medulla and the spinal cord following trigeminovascular nociceptive activation by electrical stimulation of the superior sagittal sinus (SSS) in the cat. It has been shown in the rat that N-methyl-D-aspartate (NMDA) receptor blockade causes a reduction in Fos protein expression after generalised meningeal irritation. We wished to examine if the same relationship was true in the cat, using the same non-competitive NMDA receptor antagonist MK-801, and a trigeminovascular-specific stimulus. A group of experimental animals underwent stimulation following blinded administration of MK-801 (4 mg/kg i.v.); control animals underwent stimulation minus MK-801, and a non-stimulated control animal underwent surgery alone. The regions examined for Fos-like immunoreactivity were the trigeminal nucleus caudalis (TNC) and its caudal extension into the C(1) and C(2) levels of the upper cervical spinal cord. The Fos-positive cell counts for the three regions (TNC, C(1) and C(2)) were grouped together for analysis. In the control stimulated group a median of 78 (56-99, quartile range, n=4) cells were Fos-positive. In the group treated with MK-801 the median number of Fos-positive cells was reduced to 40 (30-48; P<0.03, n=7). The large reduction that was observed in SSS stimulation-evoked Fos protein expression following the administration of MK-801, taken together with electrophysiological data, indicates a role for glutamate in neurotransmission within the trigeminocervical complex. Understanding glutamatergic mechanisms in the trigeminocervical complex offers mechanistic insight and therapeutic possibilities for primary neurovascular headaches, such as migraine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430892     DOI: 10.1016/s0006-8993(01)02550-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

2.  Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model.

Authors:  K Y Chan; S Gupta; R de Vries; A H J Danser; C M Villalón; E Muñoz-Islas; A Maassenvandenbrink
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

Review 4.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 5.  Advances in the pathophysiology of tension-type headache: from stress to central sensitization.

Authors:  Yaniv Chen
Journal:  Curr Pain Headache Rep       Date:  2009-12

Review 6.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 7.  Glutamate receptor antagonists in the management of migraine.

Authors:  Kayi Chan; Antoinette MaassenVanDenBrink
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

8.  Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 9.  Is migraine a neuropathic pain syndrome?

Authors:  David M Biondi
Journal:  Curr Pain Headache Rep       Date:  2006-06

10.  Casein kinase iδ mutations in familial migraine and advanced sleep phase.

Authors:  K C Brennan; Emily A Bates; Robert E Shapiro; Jekaterina Zyuzin; William C Hallows; Yong Huang; Hsien-Yang Lee; Christopher R Jones; Ying-Hui Fu; Andrew C Charles; Louis J Ptáček
Journal:  Sci Transl Med       Date:  2013-05-01       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.